{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:09:52Z","timestamp":1789708192646,"version":"4.0.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.xphs.2017.04.019","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T06:01:24Z","timestamp":1492754484000},"page":"1933-1943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril"],"prefix":"10.1016","volume":"106","author":[{"given":"Roger K.","family":"Verbeeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadore","family":"Kanfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimar","family":"L\u00f6benberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertil","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Cristofoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.W.","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Langguth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Parr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.xphs.2017.04.019_bib1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/jps.20131","article-title":"Biowaiver monographs for immediate release solid oral dosage forms based on Biopharmaceutics Classification System (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol","volume":"93","author":"Vogelpoel","year":"2004","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2017.04.019_bib3","series-title":"Guidance for Industry: Waiver of in\u00a0Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System","year":"2000"},{"key":"10.1016\/j.xphs.2017.04.019_bib4","series-title":"Guideline on the Investigation of Bioequivalence","year":"2010"},{"key":"10.1016\/j.xphs.2017.04.019_bib5","series-title":"Biopharmaceutics Classification System Based Biowaiver","year":"2014"},{"key":"10.1016\/j.xphs.2017.04.019_bib6","series-title":"Biopharmaceutics Classification System (BCS)","year":"2009"},{"key":"10.1016\/j.xphs.2017.04.019_bib7","series-title":"Draft\u2014Guidance for Industry: Waiver of In\u00a0Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System","year":"2015"},{"key":"10.1016\/j.xphs.2017.04.019_bib8","first-page":"971","volume":"Vol 2","year":"2004"},{"issue":"3","key":"10.1016\/j.xphs.2017.04.019_bib9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2165\/00003495-199243030-00005","article-title":"Enalapril: a reappraisal of its pharmacology and therapeutic use in hypertension","volume":"43","author":"Todd","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.xphs.2017.04.019_bib10","series-title":"Analytical Profiles of Drug Substances","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0099-5428(08)60557-2","article-title":"Enalapril maleate","author":"Ip","year":"1987"},{"key":"10.1016\/j.xphs.2017.04.019_bib11","series-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","first-page":"721","article-title":"Renin and angiotensin","author":"Hillal-Dandan","year":"2011"},{"issue":"2 S","key":"10.1016\/j.xphs.2017.04.019_bib12","doi-asserted-by":"crossref","first-page":"201S","DOI":"10.1111\/j.1365-2125.1984.tb02599.x","article-title":"The chemistry of enalapril","volume":"18","author":"Patchett","year":"1984","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2017.04.019_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.addr.2003.10.011","article-title":"Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs)","volume":"56","author":"Raw","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"issue":"2-3","key":"10.1016\/j.xphs.2017.04.019_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0378-5173(86)90244-9","article-title":"High resolution spectroscopic evidence and solution calorimetry studies on the polymorphs of enalapril maleate","volume":"28","author":"Ip","year":"1986","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2017.04.019_bib15","first-page":"347","article-title":"Enalapril maleate polymorphs: instability of form II in a tablet formulation","volume":"57","author":"Eyjolfsson","year":"2002","journal-title":"Pharmazie"},{"issue":"5","key":"10.1016\/j.xphs.2017.04.019_bib16","first-page":"357","article-title":"Enalapril maleate form II: stabilization in a tablet formulation","volume":"58","author":"Eyjolfsson","year":"2003","journal-title":"Pharmazie"},{"key":"10.1016\/j.xphs.2017.04.019_bib17","series-title":"Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations","year":"2017"},{"key":"10.1016\/j.xphs.2017.04.019_bib18","series-title":"Draft guidance on enalapril maleate","year":"2008"},{"issue":"1","key":"10.1016\/j.xphs.2017.04.019_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"1","author":"Kasim","year":"2004","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2017.04.019_bib20","doi-asserted-by":"crossref","first-page":"7F","DOI":"10.1016\/S0002-9149(99)80508-6","article-title":"Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor","volume":"75","author":"Razetti","year":"1995","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.xphs.2017.04.019_bib21","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1023\/A:1015823315983","article-title":"Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors","volume":"9","author":"Ranadive","year":"1992","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2017.04.019_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0928-0987(01)00190-7","article-title":"pH-metric solubility.: 3. Dissolution titration template method for solubility determination","volume":"14","author":"Avdeef","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2017.04.019_bib23","series-title":"Prodrugs and Targeted Delivery","first-page":"81","article-title":"Increasing lipophilicity for oral drug delivery","author":"Moridani","year":"2011"},{"issue":"14","key":"10.1016\/j.xphs.2017.04.019_bib24","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3109\/03639048609063193","article-title":"Effect of moisture on the physical and chemical stability of granulations and tablets of the angiotensin converting enzyme inhibitor, enalapril maleate","volume":"12","author":"Shiromani","year":"1986","journal-title":"Drug Dev Ind Pharm"},{"issue":"5-6","key":"10.1016\/j.xphs.2017.04.019_bib25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0731-7085(01)00399-5","article-title":"Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations","volume":"25","author":"Al-Omari","year":"2001","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"1-2","key":"10.1016\/j.xphs.2017.04.019_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0378-5173(87)90058-5","article-title":"Drug-excipient interaction study of enalapril maleate using thermal analysis and scanning electron microscopy","volume":"40","author":"Cotton","year":"1987","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2017.04.019_bib27","first-page":"378","article-title":"Design and evaluation of a new formulations of enalapril maleate 20 mg tablet in a time efficient and on a large industrial scale","volume":"6","author":"Kello","year":"2014","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.xphs.2017.04.019_bib28","series-title":"Stable formulation of enalapril salt, a process for the preparation thereof and the use thereof. ed.: Google patents","author":"Merslavic","year":"1994"},{"issue":"3","key":"10.1016\/j.xphs.2017.04.019_bib29","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1208\/s12249-013-0006-6","article-title":"Effect of stearic acid on enalapril stability and dissolution from multiparticulate solid dosage forms","volume":"14","author":"Cunha","year":"2013","journal-title":"AAPS Pharm Sci Tech"},{"key":"10.1016\/j.xphs.2017.04.019_bib30","series-title":"Guidance for Industry; Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients","year":"2001"},{"issue":"1","key":"10.1016\/j.xphs.2017.04.019_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/03602538308991383","article-title":"Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man","volume":"14","author":"Ulm","year":"1983","journal-title":"Drug Metab Rev"},{"issue":"4","key":"10.1016\/j.xphs.2017.04.019_bib33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2165\/00003088-199325040-00003","article-title":"Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships: an overview","volume":"25","author":"MacFadyen","year":"1993","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.xphs.2017.04.019_bib34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2125.1982.tb01991.x","article-title":"Enalapril maleate and a lysine analogue (MK-521): disposition in man","volume":"14","author":"Ulm","year":"1982","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2017.04.019_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0090-9556(25)07829-8","article-title":"The physiological disposition and metabolism of enalapril maleate in laboratory animals","volume":"10","author":"Tocco","year":"1982","journal-title":"Drug Metab Disposition"},{"issue":"3","key":"10.1016\/j.xphs.2017.04.019_bib36","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ejpb.2011.11.011","article-title":"Assessment of enzymatic prodrug stability in human, dog and simulated intestinal fluids","volume":"80","author":"Borde","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"issue":"suppl 2","key":"10.1016\/j.xphs.2017.04.019_bib37","doi-asserted-by":"crossref","first-page":"215S","DOI":"10.1111\/j.1365-2125.1984.tb02601.x","article-title":"An overview of the clinical pharmacology of enalapril","volume":"18","author":"Davies","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2017.04.019_bib38","first-page":"248","article-title":"Bioavailability of enalapril maleate","volume":"33","author":"Irvin","year":"1984","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.xphs.2017.04.019_bib39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/bdd.2510050309","article-title":"Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers","volume":"5","author":"Till","year":"1984","journal-title":"Biopharm Drug Disposition"},{"issue":"2","key":"10.1016\/j.xphs.2017.04.019_bib40","first-page":"275","article-title":"Pharmacodynamics and disposition of intravenous MK-422, the diacid metabolite of enalapril maleate","volume":"31","author":"Till","year":"1982","journal-title":"Clin Pharmacol Ther"},{"issue":"1-2","key":"10.1016\/j.xphs.2017.04.019_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.07.009","article-title":"The gastrointestinal microbiota as a site for the biotransformation of drugs","volume":"363","author":"Sousa","year":"2008","journal-title":"Int J Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2017.04.019_bib42","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/jps.2600731146","article-title":"Influence of food on the bioavailability of enalapril","volume":"73","author":"Swanson","year":"1984","journal-title":"J\u00a0Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2017.04.019_bib43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/js970332a","article-title":"Human intestinal permeability","volume":"87","author":"Lennern\u00e4s","year":"1998","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2017.04.019_bib44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A\u00a0theoretical basis for a biopharmaceutic drug classification: the correlation of in\u00a0vitro drug product dissolution and in\u00a0vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2017.04.019_bib45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1211\/0022357055263","article-title":"The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension","volume":"57","author":"Lennern\u00e4s","year":"2005","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"suppl 2","key":"10.1016\/j.xphs.2017.04.019_bib46","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0928-0987(00)00163-9","article-title":"Membrane transporters","volume":"11","author":"Lee","year":"2000","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2017.04.019_bib47","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1023\/A:1018982505021","article-title":"Intestinal peptide transport systems and oral drug availability","volume":"16","author":"Yang","year":"1999","journal-title":"Pharm Res"},{"issue":"7","key":"10.1016\/j.xphs.2017.04.019_bib48","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1023\/A:1016071027177","article-title":"Suitability of enalapril as a probe of the dipeptide transporter system: in\u00a0vitro and in\u00a0vivo studies","volume":"13","author":"Morrison","year":"1996","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2017.04.019_bib49","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1124\/jpet.108.143339","article-title":"Transport of angiotensin-converting enzyme inhibitors by H\u00a0+\/peptide transporters revisited","volume":"327","author":"Kn\u00fctter","year":"2008","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"2 A","key":"10.1016\/j.xphs.2017.04.019_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0002-9343(84)80055-8","article-title":"Enalapril worldwide experience","volume":"77","author":"Davies","year":"1984","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.xphs.2017.04.019_bib51","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/dmd.113.053512","article-title":"In\u00a0vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors","volume":"42","author":"Thomsen","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.xphs.2017.04.019_bib52","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1124\/dmd.106.009381","article-title":"Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine","volume":"34","author":"Imai","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2017.04.019_bib53","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1124\/jpet.106.103390","article-title":"Vectorial transport of enalapril by Oatp1a1\/Mrp2 and OATP1B1 and OATP1B3\/MRP2 in rat and human livers","volume":"318","author":"Liu","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.xphs.2017.04.019_bib54","first-page":"G156","article-title":"A\u00a0novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane","volume":"278","author":"K\u00f6nig","year":"2000","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.xphs.2017.04.019_bib55","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.clinthera.2011.04.018","article-title":"Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men","volume":"33","author":"Tian","year":"2011","journal-title":"Clin Ther"},{"issue":"4-5","key":"10.1016\/j.xphs.2017.04.019_bib56","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jpba.2008.02.030","article-title":"Stability and in\u00a0vitro release profile of enalapril maleate from different commercially available tablets: possible therapeutic implications","volume":"47","author":"Lima","year":"2008","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"5","key":"10.1016\/j.xphs.2017.04.019_bib57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s002280050130","article-title":"Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers: pharmacokinetic versus pharmacodynamic approach","volume":"50","author":"Ribeiro","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.xphs.2017.04.019_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/bdd.368","article-title":"Bioequivalence evaluation of two brands of enalapril 20 mg tablets (Narapril and Renitec) in healthy human volunteers","volume":"24","author":"Najib","year":"2003","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2017.04.019_bib59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0011-393X(04)90003-3","article-title":"Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): a randomized, two-way, open-label, crossover study in healthy volunteers","volume":"65","author":"Portol\u00e9s","year":"2004","journal-title":"Curr Ther Res"},{"issue":"5","key":"10.1016\/j.xphs.2017.04.019_bib60","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5414\/CPP41226","article-title":"Bioequivalence study of two brands of enalapril tablets after single oral administration to healthy volunteers","volume":"41","author":"Niopas","year":"2003","journal-title":"Int J Clin Pharm Ther"},{"issue":"7","key":"10.1016\/j.xphs.2017.04.019_bib61","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5414\/CPP38327","article-title":"Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation","volume":"38","author":"Lo","year":"2000","journal-title":"Int J Clin Pharm Ther"},{"key":"10.1016\/j.xphs.2017.04.019_bib62","series-title":"Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products\u2014General Considerations","year":"2003"},{"issue":"1","key":"10.1016\/j.xphs.2017.04.019_bib65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0939-6411(00)00091-6","article-title":"Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards","volume":"50","author":"Lobenberg","year":"2000","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"10.1016\/j.xphs.2017.04.019_bib66","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1023\/A:1016473601633","article-title":"Biopharmaceutics Classification System: the scientific basis for biowaiver extensions","volume":"19","author":"Yu","year":"2002","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2017.04.019_bib67","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0928-0987(99)00076-7","article-title":"The Biopharmaceutics Classification System (BCS): class III drugs\u2014better candidates for BA\/BE waiver?","volume":"9","author":"Blume","year":"1999","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2017.04.019_bib68","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejps.2004.03.016","article-title":"Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet","volume":"22","author":"Cheng","year":"2004","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2017.04.019_bib69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003088-200645040-00004","article-title":"Feasibility of biowaiver extension to Biopharmaceutics Classification System Class III drug products: cimetidine","volume":"45","author":"Jantratid","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2017.04.019_bib70","series-title":"Dissolution Testing and Specification Criteria for Immediate-release Solid Oral Dosage Forms Containing Biopharmaceutics Classification System Class 1 and 3 Drugs","year":"2015"},{"key":"10.1016\/j.xphs.2017.04.019_bib71","first-page":"1","article-title":"BCS biowaivers: similarities and differences among EMA, FDA, and WHO requirements","author":"Davit","year":"2016","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.xphs.2017.04.019_bib72","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1590\/S0101-28002010000200006","article-title":"Meta-analysis for bioequivalence studies: interchangeability of generic drugs and similar containing hydrochlorothiazide is possible but not with enalapril maleate","volume":"32","author":"Lopes","year":"2010","journal-title":"J\u00a0Brasil Nefrol"},{"issue":"1 special issue","key":"10.1016\/j.xphs.2017.04.019_bib73","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2006.10.001","article-title":"Current perspectives in dissolution testing of conventional and novel dosage forms","volume":"328","author":"Azarmi","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2017.04.019_bib74","series-title":"Orange book preface","year":"2016"},{"issue":"10","key":"10.1016\/j.xphs.2017.04.019_bib75","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2165\/00003088-200443100-00002","article-title":"Metabolites and bioequivalence: past and present","volume":"43","author":"Jackson","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2017.04.019_bib76","series-title":"Generic Drug Product Development: Bioequivalence Issues","first-page":"171","article-title":"Role of metabolites in bioequivalence assessment","author":"Jackson","year":"2008"},{"issue":"4","key":"10.1016\/j.xphs.2017.04.019_bib77","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2165\/00003495-199549040-00003","article-title":"Choosing the right ACE inhibitor: a guide to selection","volume":"49","author":"Leonetti","year":"1995","journal-title":"Drugs"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917302538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917302538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T23:31:34Z","timestamp":1750203094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354917302538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0022354917302538"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2017.04.019","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2017.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}